TOKYO -- Takeda Pharmaceutical will purchase a piece of the U.S. biotechnology startup Nimbus Therapeutics for $4 billion, the Japanese drugmaking giant said Tuesday, as it seeks to secure what is expected to be the next blockbuster drug.
Takeda will buy all shares of Nimbus Lakshmi, a subsidiary of Nimbus Therapeutics. Not only will Takeda transfer the $4 billion as a lump-sum payment, the company will also pay Nimbus Therapeutics additional sales-based milestone payments.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
